Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,070Revenue (TTM) $M118Net Margin (%)-16.3Altman Z-Score-3.7
Enterprise Value $M1,002EPS (TTM) $-0.6Operating Margin %-11.4Piotroski F-Score4
P/E(ttm)--Beneish M-Score-0.1Pre-tax Margin (%)-17.2Higher ROA y-yY
Price/Book10.510-y EBITDA Growth Rate %-34.0Quick Ratio3.1Cash flow > EarningsN
Price/Sales5.75-y EBITDA Growth Rate %-30.0Current Ratio3.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-10.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-57.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M39.2ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with ARNA

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ARNA is held by these investors:



ARNA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Munshi AmitPresident and CEO 2017-05-12Buy2,500$11.9129.24view
Munshi AmitPresident and CEO 2017-04-26Buy5,000$14.193.48view
White Christine AnnaDirector 2016-06-13Sell1,873$19.937.09view
WOODS RANDALL EDirector 2015-03-30Sell7,627$44.9-39.24view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-03-17Sell7,000$50-45.44view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-01-08Sell4,500$62.6-56.42view
SHANAHAN WILLIAM R JRSVP & Chief Medical Officer 2015-01-07Sell5,000$54.9-50.31view
LIEF JACKChairman, President and CEO 2014-07-01Sell22,353$58.5-53.37view
BELCHER DONALD DDirector 2014-06-27Sell247$58.5-53.37view
SPECTOR STEVEN WEVP, General Counsel & Sec 2014-05-12Sell4,500$70.5-61.3view

Press Releases about ARNA :

Quarterly/Annual Reports about ARNA:

News about ARNA:

Articles On GuruFocus.com
Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepa Oct 19 2017 
Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonar Sep 06 2017 
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences Aug 29 2017 
Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonar Aug 22 2017 
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results Aug 07 2017 
Arena Pharmaceuticals to Release Second Quarter 2017 Financial Results and Provide Corporate Update Jul 31 2017 
Arena Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares Jul 31 2017 
Wall Street Opens Stable With Yellen in 2nd Day of Testimony Jul 13 2017 
Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock Jul 12 2017 
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock Jul 11 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK